Business Context and Reporting Period
Company: Proteon Therapeutics, Inc. (Note: Input metadata references "Protara," but the filing text identifies the registrant as Proteon Therapeutics, Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: August 8, 2016
Reporting Period: Second quarter ended June 30, 2016
Context: This filing announces the issuance of a press release detailing financial results for the second quarter of 2016. The press release is attached as Exhibit 99.1 and incorporated by reference.
Key Financial Metrics
The provided Form 8-K text serves as a notification of the results and does not contain specific financial data points. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the attached press release (Exhibit 99.1), which is not included in the input text.
Material Changes
The filing text does not disclose specific material changes versus the prior comparable period. It only confirms that financial results for the quarter ended June 30, 2016, have been announced.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, forward-looking guidance, specific risk factors, or details on contingencies and unusual items. Such information is referenced as being included in the attached press release (Exhibit 99.1).
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) in the attached Exhibit 99.1 press release.
- Confirm the company name discrepancy between the request metadata ("Protara") and the filing text ("Proteon Therapeutics, Inc.").
- Review the press release for any updates on clinical trial progress or regulatory milestones, as this is a biopharmaceutical company.
- Check for any forward-looking statements or guidance provided in the full press release text.